- 1 Title: Effectiveness and cost-effectiveness of a culturally tailored Behavioural Activation
- 2 intervention (DiaDeM) for treating Depression in Type 2 Diabetes: Protocol for a parallel arm,
- 3 multi-country, randomised controlled trial in South Asia
- 4

5 Authors:

- 6 Faraz Siddiqui^{1*}, Faiza Aslam², Naveed Ahmed³, Saima Afaq^{1,4,5}, Asima Khan⁶, Ada Keding^{1,7},
- 7 Simon Walker⁸, Hannah Maria Jennings^{1,9}, Gerardo A Zavala¹, David Ekers^{1,10}, Edward
- 8 Fottrell¹¹, Catherine Hewitt^{1,7}, Zia UI Haq⁴ and Najma Siddiqi^{1,9} on behalf of the DiaDeM Global
- 9 Health Research Group
- 10

11 Institutional Affiliations:

- ¹Department of Health Sciences, University of York, Heslington, York, YO10 5DD, UK
- ¹³ ² Institute of Psychiatry, Rawalpindi Medical University, Rawalpindi, Punjab, 23000, Pakistan
- ³ Diabetic Association of Bangladesh, BIRDEM General Hospital, Dhaka, 1000, Bangladesh
- ⁴ Institute of Public Health, Khyber Medical University, Peshawar, Khyber Pakhtunkhwa, 25100,
- 16 Pakistan
- ⁵ School of Public Health, Imperial College London, London, W2 1PG, UK
- ⁶ Baqai Institute of Diabetes and Endocrinology, Karachi, Sindh 74600, Pakistan
- ⁷ York Trials Unit, Department of Health Sciences, University of York, Heslington, York, YO10
- 20 5DD, UK
- ⁸ Centre for Health Economics, University of York, Heslington, York, YO10 5DD, UK
- 22 ⁹ Hull York Medical School, Heslington, York YO10 5DD
- 23 ¹⁰ Tees, Esk and Wear Valleys NHS Foundation Trust, YO30 4XT
- 24 ¹¹UCL Institute for Global Health, University College London, London, WC1N 1EH, UK
- 25 Hull York Medical School, Heslington, York, YO10 5DD, UK

27 *Correspondence address

- 28 Email: faraz.siddiqui@york.ac.uk
- 29 Address: Department of Health Sciences, University of York, Heslington YO10 5DD

30 Abstract: (340 words)

31 Background:

The co-occurrence of depression among individuals with type 2 diabetes is a recognised global health problem and can lead to poorer health outcomes for both conditions. Behavioural activation is an evidence-based brief, low-cost psychological therapy which can be delivered by trained non-specialists, and is useful in treating depression, particularly in low-resource settings. The aim of this study is to test the effectiveness and cost-effectiveness of culturally adapted behavioural activation for depression in people with both depression and type 2 diabetes in two South Asian countries - Bangladesh and Pakistan.

39

40 Methods:

A parallel arm, multi-country randomised controlled trial will be conducted in urban health care 41 42 facilities providing diabetes services. We will recruit 604 adults in total, and randomise them 43 using a 1:1 allocation ratio to receive culturally adapted behavioural activation (DiaDeM), or optimised usual care. DiaDeM comprises six sessions of behavioural activation with a trained 44 45 non-mental health facilitator, conducted face-to-face and/or remotely. Optimised usual care 46 includes information on depression, pharmacological and non-pharmacological treatment options for depression and details for accessing help locally. Participants in both arms will be 47 followed up at 6- and 12-months post-randomisation. The primary outcome is the severity of 48 49 depressive symptoms at 6 months, measured using the 9-item Patient Health Questionnaire 50 (PHQ-9). Secondary outcomes include diabetes control, measured using glycosylated 51 haemoglobin. An embedded process evaluation will evaluate the quality of intervention delivery 52 and explore mechanisms of change and the contextual factors associated with the 53 implementation and observed outcomes of DiaDeM. An economic evaluation will gauge 54 DiaDeM's cost-effectiveness and estimate the impact of diabetes and depression on economic 55 outcomes.

56

57 Conclusion:

- 58 There is an urgent need to address the rising burden of depression and chronic physical
- 59 illnesses, such as type 2 diabetes. Interventions such as DiaDeM, which are culturally relevant
- and rely on a task-sharing approach, offer a potentially low-cost treatment within existing health
- 61 services. If found to be effective and cost-effective, DiaDeM may be scaled up to address the
- 62 mental health 'treatment gap' and improve mental and physical health outcomes for people with
- 63 diabetes in South Asia.
- 64
- 65 Trial registration: ISRCTN40885204. Trial registered on 11th April 2023

- 67 **Keywords:** Behavioural activation; intervention adaptation; Diabetes; Depression;
- 68 Multimorbidity; South Asia; Low and Middle-Income countries

70 Background

71 Type 2 diabetes is a chronic non-communicable disease (NCD) associated with a 72 disproportionately higher risk of having comorbid mental health conditions, particularly depression 73 [1]. The two conditions have a bi-directional relationship - individuals with diabetes have double the risk of developing depression as compared to the general population [2-4], and having 74 75 persistent depression also raises the risk of developing diabetes later in life [5]. Having depression 76 alongside diabetes may impede diabetes self-care, causing a subsequent lack of control of 77 overlapping risk factors such as diet and physical activity, and deterioration in the overall quality of life [2,3]. It also results in significantly higher healthcare use and expenditure as compared to 78 79 diabetes alone [6]. These effects are likely to more severely impact populations in low-resource 80 settings, particularly in low and middle-income countries (LMICs) where approximately 80% of individuals living with diabetes reside worldwide [7,8]. South Asia is a typical example of such 81 82 low-resource, high-burden settings. Published literature from South Asian settings estimates the 83 prevalence of diabetes to be as high as 26% [9], with at least a guarter of such individuals also 84 having co-morbid depression [10,11].

85 Psychological therapies are increasingly being recognised for their relevance to the treatment of common mental disorders in people with diabetes, particularly because of their consideration of 86 87 the wider psychosocial aspects of illness, and they have proven to be effective to reduce depressive symptoms in people with NCDs in LMICs [12]. Behavioural activation (BA) is a type of 88 psychological treatment, recognised for its parsimony, portability across cultures and efficiency of 89 90 training. It is a relatively simple, low-cost treatment, with established effectiveness for the 91 treatment of depression in a range of settings and populations [13]. BA conceptualises depression in terms of the interaction between an individual and their environment; it helps people understand 92 the link between mood and activities and encourages them to identify and engage in meaningful 93

and rewarding activities as a means to improve depression [14,15]. BA treatment is widely 94 accepted and is considered an economical alternative to, or adjunct to pharmacological treatment 95 [16]. It can be effectively delivered by mental health staff, as well as trained non-mental health 96 specialists [17,18]. Given these qualities, BA could be particularly relevant for LMIC populations 97 98 and for priority groups such as those with co-occurring physical and mental Illnesses. It can overcome resource constraints in the provision of staged therapies and pharmacological 99 100 interventions, and potentially contribute to reducing the burden of depression in people with diabetes. To date, only two clinical trials have evaluated the use of BA for the treatment of 101 102 depression among individuals living with NCDs. Both were conducted in the United States, and only one demonstrated short and medium-term effectiveness in the remission of depression [19]. 103 This evidence is limited, inconclusive and has little relevance for LMICs. Further high-quality 104 studies are needed to evaluate the effectiveness and cost-effectiveness of BA for people with 105 106 NCDs such as diabetes.

We have recently demonstrated the feasibility and acceptability of a culturally adapted BA intervention (the Diabetes and Depression Multimorbidity intervention - henceforth "DiaDeM") to treat depression in people with diabetes in Bangladesh and Pakistan [14]. Building on this, we now aim to carry out a full-scale trial to test the effectiveness and cost-effectiveness of DiaDeM in these settings. Our objectives are to:

Evaluate the clinical effectiveness of the DiaDeM intervention in reducing the severity of
 depression at 6 months, compared with optimised usual care

Evaluate the clinical effectiveness of the DiaDeM intervention on secondary outcomes,
 compared with optimised usual care at 6 and 12 months

116	3.	Evaluate the cost-effectiveness of the DiaDeM intervention over the trial period as well
117		as the lifetime of affected individuals, considering the healthcare system and other
118		broader perspectives
119	4.	Estimate the causal impact of diabetes and depression on economic outcomes such as
120		employment status, productivity loss, catastrophic health spending, household
121		expenditure and household assets
122	5.	Assess the fidelity and quality of intervention delivery, and identify the mechanisms of
123		change and contextual factors associated with the implementation and outcomes of the
124		DiaDeM intervention

125 Methods

126 Study design:

127 The study is a multi-country, parallel arm, randomised controlled trial which will test the 128 effectiveness and cost-effectiveness of the DiaDeM intervention compared to optimised usual 129 care (control), and includes an embedded mixed-method process evaluation. The trial protocol (v1.0, dated 20/1/2023) was developed, and is reported in accordance with the Standard 130 131 Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines for clinical trial protocols (supplementary file 1) and the Template for Intervention Description and Replication 132 133 (TIDieR) checklist (supplementary file 2) [20]. The DiaDeM trial was launched on 6th March 134 2023 and is currently in the recruitment phase. The activities related to trial recruitment, intervention delivery and follow-up assessments, and the overall flow of the trial are presented 135 136 in Figures 1 and 2 respectively.

137

139									
140									
141									
142	Figure1. SPIRIT schedule of trial recruitment and follow-up, intervention delivery and								
143		assessments							
144	Figure	2. Flow diagram representing the recruitment, randomisation and follow up procedures of							
145		the DiaDeM trial							
146	Study	settings and locations:							
147	The D	iaDeM trial is being conducted in five urban health care facilities in South Asian settings							
148	that provide diabetes related services. Three of these sites are based in Pakistan (Karachi,								
149	Pesha	war, and Rawalpindi) and two in Bangladesh (Dhaka, Sylhet). The chosen sites have well							
150	establi	ished diabetes services and available healthcare staff within these to deliver the DiaDeM							
151	interve	ention and have adequate research infrastructure. The sites are (in alphabetic order):							
152	1.	Baqai Institute of Diabetes and Endocrinology (BIDE), Karachi, Sindh, Pakistan.							
153	2.	Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and							
154		Metabolic Disorders (BIRDEM) General Hospital, Dhaka, Bangladesh.							
155	3.	Sugar Hospital, Phase V, Hayatabad, Peshawar, Pakistan							
156	4.	Sughra Diabetic Centre, Benazir Bhutto Hospital, Rawalpindi, Pakistan							
157	5.	Sylhet Diabetic Hospital, Sylhet, Bangladesh							
158	Eligib	ility criteria:							
159	This tr	ial will be conducted in a sample of individuals who have a confirmed diagnosis of type 2							

161 study sites in Bangladesh and Pakistan. Eligible individuals will be identified based on the

- 162 following criteria:
- 163 Age \geq 18 years old at the time of screening/recruitment
- Confirmed physician diagnosis of type 2 diabetes based on standardised diagnostic
- 165 criteria (clinical presentation and HbA1C levels) and currently receiving treatment at the
- 166 diabetes centre
- Scoring ≥3 on the Patient Health Questionnaire-2 (PHQ-2)[21] depression screening
- tool, and subsequently scoring \geq 5 on the Patient Health Questionnaire-9 (PHQ-9)[22]
- 169 with depression confirmed using the current major depressive disorder section of module
- 170 A "Mood Episodes and Disorders" of the Research Version of the Structured Clinical
- 171 Interview for the DSM-V (SCID-V-RV)[23]
- Willingness to attend BA sessions in person or remotely
- 173

174 Individuals in any of the following categories will not be eligible for trial participation.

- Currently receiving psychotherapy for depression at the time of screening/recruitment

Unable to provide consent due to cognitive impairment or severity of psychological or
 physical illness

178 Screening and identification of eligible participants:

Eligible participants will be identified using a two-stage process. In the first stage, patients attending outpatient clinics at each study site will be screened for depressive symptoms by clinical staff, using the two-item Patient Health Questionnaire (PHQ-2). Positively screened individuals will be provided information about the importance of depression screening (leaflet 1) (supplementary file 3) and where to access help; those who agree to further screening will be taken to phase 2 following written consent for the screening of depression (Supplementary file

4). Each individual will be assigned a unique screening ID at this stage and will be assessed
further by a research assistant (RA) for depression using the Urdu or Bangla versions of the
nine-item PhQ-9 followed by the Current Major Depressive Disorder section of module A of the
SCID-V.

189 The RAs will check, confirm and record the eligibility of the identified individuals for trial

190 participation. Those who score positive on both PHQ 9 (score ≥5) and SCID-V and fulfil the

remaining eligibility criteria described above will be taken forward for full consent for trial

192 participation.

193 Informed consent and recruitment:

RAs will provide eligible individuals with a local language (Urdu or Bangla) version of the participant information sheet (Supplementary file 5), which provides details about the trial, its methods and assessment procedures, as well as any possible advantages and risks associated with participation. The opportunity to read the information sheet will be given to eligible participants; those who are unable to read will have the information sheet read out to them. Participants will be made aware of their rights, including the right to withdraw from the study at any time and the procedure to follow in such a situation.

After the information sheet has been read, the RAs will provide a study consent form (Supplementary file 6) to the participants to read and confirm their participation. Written consent will be recorded. Following consent, the recruited participant will be taken forward to baseline data collection and then randomised. The participant's consent status and contact information will be recorded in a participant log and an electronic database.

206 **Randomisation and blinding:**

After completion of the baseline Case Report Form (CRF), each recruited participant will be 207 208 randomly allocated to either the treatment or control arm. Randomisation will use a 1:1 allocation 209 ratio and will follow a computer-generated randomisation sequence that will be stratified by 210 country with randomly permuted blocks of varying block sizes, generated using Stata version 17 or later (StataCorp, 4905 Lakeway Drive, College Station, Texas, 77845 USA). A request for 211 randomisation will be made to the independent statistician based at the University of York. This 212 213 will be done via email by the site RA or by the country data manager in case of internet disruption at the study site. An automated email will be sent back to the RA and data manager containing 214 215 the trial ID and allocation. The trial ID will be recorded on the completed baseline CRF and the recruitment log. The trial manager and the RAs collecting outcome data at the follow-up stage will 216 217 be blinded to participant allocation status.

218 **Details of Intervention and Control:**

Behavioural activation (DIADEM): The DiaDeM BA intervention is a culturally adapted, brief, 219 220 psychological therapy for depression which focuses on behaviour change to enhance mental and physical well-being for people living with depression and diabetes multimorbidity. The intervention 221 was adapted from the Multimorbidity in older adults intervention (MODS) [24] programme using 222 223 the intervention mapping framework for the development, implementation and evaluation of health 224 promotion interventions [25]. This framework provides a structured approach for the development and evaluation of health interventions. Additionally, the Bernal [26] and Escoffery [27] frameworks 225 226 were employed to specifically address the cultural components of the adaptation process. These 227 frameworks facilitated a comprehensive and systematic adaptation of DiaDeM, ensuring that it 228 was culturally relevant and appropriate for the South Asian population. As part of the adaptation 229 process, we developed a logic model based on the desired outcome "to improve depression in

people with diabetes in Bangladesh and Pakistan". To understand the "mechanisms of action"
through which the intervention affects behaviour, we identified behavioural change techniques
and the mechanisms of action they target. Full details of the adaptation process are described in
detail elsewhere [28].

DiaDeM will be delivered by non-mental health specialist staff (diabetes staff working as nutritionists, health educators, nurses, or paramedics etc). The non-mental health specialist BA facilitators (referred to henceforth as 'BA facilitators') will be guided and supervised by mental health specialists in Bangladesh and Pakistan who will be referred to as 'BA supervisors.

238

DiaDeM comprises six weekly sessions (each lasting 30-45 minutes) delivered by a BA facilitator 239 using the BA facilitator's manual. Session one will introduce the concept of the relationship 240 between mood and behaviour and between purposefully scheduling and engaging in rewarding 241 242 activities in improving symptoms of depression and self-management of diabetes. Sessions two to five are skills-based for learning and practising skills that support the participant in re-engaging 243 in personally chosen, rewarding behaviours. Each of these sessions incorporates a recap of 244 245 learning from the previous session and a review of planned between-session work. Participants 246 are supported by the BA facilitator to increase both the number of rewarding behaviours engaged 247 in week-by-week and to gradually introduce behaviours previously considered too difficult to manage as their symptoms of depression improve. Session six consolidates prior learning and 248 promotes maintenance behaviours by developing a personalised "staying well" plan. The 249 250 participants will also be given a 'participant booklet', a take-home resource that incorporates key messages from the intervention sessions as well as space in which to record information about 251 between-session behaviour change activities to practice, chosen by each participant with the 252 253 support of the BA facilitator. DiaDeM sessions will be delivered individually in private treatment 254 rooms at each study site. If the participant is unable to travel to the treatment centre, they will be offered a video call or telephone treatment session by the BA facilitator as an alternative. 255

256

257	BA facilitators and the supervisors will receive prior training in using the DiaDeM manual and
258	participant booklet to support DiaDeM treatment sessions and in supporting participants in
259	choosing between-session behaviour change activities. All the BA facilitators and supervisors
260	will attend an online, introductory course on Behavioural Activation for Depression developed by
261	the University of York (<u>https://www.impactsouthasia.com/behavioural-activation-learning/</u>) as a
262	requisite for attending the BA training. A three-day hands-on face-to-face BA training will be
263	conducted in Bangladesh and Pakistan by BA experts and therapists. Training will be conducted
264	for both facilitators and supervisors jointly, using PowerPoint presentations, individual and group
265	activities, and role-play. The supervisors will receive additional training on oversight, after which
266	they will perform the competency assessments of BA facilitators. During the intervention
267	delivery phase of the trial, the supervisors will oversee and guide the BA facilitators and will
268	conduct refresher training, if required. The supervisors will also record supervisory notes and
269	competency assessments in "supervisor's logs"; BA facilitators will record details of the BA
270	delivery sessions for each participant in the facilitator's logs.
271	
272	Optimised usual care: Optimised usual care comprises information leaflets on depression,

pharmacological and non-pharmacological treatment options for depression and the procedures
for accessing local help, provided by the study team. The leaflets were developed by the project
team in consultation with mental health experts (Supplementary file 8). The intervention group will
also receive optimised usual care.

277 Sample size:

The sample size was calculated in Stata (Version 17) and is based on sufficient power for the analysis of data in each country, although data will be combined for the primary analysis. A meta-

analysis of Behavioural Activation for depression reported a standard effect size of -0.74 (95% CI
of -0.91 to -0.56) [29]. The lower bound value of 0.5 is equivalent to a difference of approximately
2 PHQ-9 points (SD of 4). The feasible number of intervention facilitators differs in each country
setting, resulting in different potential clustering effects to account for.

In Pakistan, in order to detect the above difference with 90% power and 5% alpha, accounting for clustering by therapist (ICC of 0.04, average of 10 intervention participants per therapist) and assuming 20% attrition, a total of 294 participants is required to be recruited (147 participants in each arm). A minimum of 15 intervention facilitators is required. In Bangladesh, in order to detect the same difference, assuming an average of 12 intervention participants per therapist (minimum of 13 intervention facilitators), a total of 310 participants are required to be recruited (155 in each arm).

This sample size estimate is conservative, applying the clustering inflation factor to both study arms to maintain the randomised allocation ratio of 1:1. The achieved power for the recruitment target in each country based on clustering in the intervention arm only exceeds 97% (clsampsi command in Stata). The combined total sample size for both participating countries is 604. Assuming a conservative estimate of depression prevalence of 10% and a 60% consent rate, approximately 10,070 patients will need to be screened.

297 Primary and secondary trial outcomes:

The primary trial outcome will be the severity of depressive symptoms, assessed using the PHQ-9 instrument at 6 months post-randomisation. This is a nine-item questionnaire scored from a minimum of 0 to a maximum of 27 [22,30]. Secondary trial outcomes are depression (caseness), anxiety, diabetes self-management, glycaemic control, BMI, diabetes distress, cardiometabolic outcomes, health-related guality of life, healthcare costs, adverse events at 6

and 12 months; severity of depressive symptoms at 12 months. Details of how and when these
outcomes will be measured are provided in the text below.

305 Baseline and follow-up data collection:

Baseline participant data will be obtained before randomisation at the time of recruitment.

307 Follow-up participant data will be collected 6 months and 12 months post-randomisation. RAs

308 will use electronic CRFs to collect information either face-to-face, or remotely (in case of

309 COVID-19 restrictions, or if not feasible to travel) at all time points. To reduce the risk of

unbliding the treatment allocation, the RAs will be switched at follow-up time points. The details

of each planned assessment are provided below, and the time-points at which these will be

312 collected are presented in Figure 1.

313 <u>Socio-demographic information:</u> The WHO Stepwise approach to surveillance (STEPs)

instrument, Version 3.2 [31] will be used to collect information about participants' age, sex,

315 education and marital status. Translated versions of this instrument have been used and

validated in different countries of South Asia including Bangladesh [32] and Pakistan [33].

317 <u>Anthropometric and physical body measurements:</u> The following physical body measurements 318 will be taken by trained RAs following the protocols elaborated in the WHO manual [34].

Weight (in kilograms) will be measured using a portable digital weighing scale will be
 used at all sites. The weighing scale will be placed on a flat surface - two repeated
 readings will be collected and recorded to two decimal places. Participants will be
 instructed to wear light clothing and to remove footwear and socks at the time of
 weighing.

Height (in centimetres) will be measured using a portable stadiometer, without footwear
 and headgear. Two consecutive readings will be recorded to 0.1 cm.

Body Mass Index will be calculated as weight in kilograms (kgs) divided by height in
 meters squared (kg/m²). and recorded in the electronic tablet.

Waist circumference (in centimeters) will be measured at the midpoint between the lower
 margin of the last palpable rib and the top of the iliac crest (hip bone) with a relaxed
 arms position and fully exhaling process at the end of expiration. Two repeated readings

331 will be recorded with a precision of 0.1 cm.

Hip circumference (in centimeters) measurement will be recorded using a flexible
 anthropometric tape by wrapping the tape around the widest part of the buttocks, and
 taking the parallel to the floor. Two repeated readings will be recorded in centimetres
 with a precision of 0.1 cm.

The waist-hip ratio will be calculated by dividing the waist circumference by the hip
 circumference, and recorded on the electronic tablet.

Blood pressure and heart rate will be measured with the help of an automated blood pressure measuring instrument. Three consecutive readings will be recorded (each with a 3-minute gap) from the same wrist/elbow and using the same device. The participant will be comfortably seated at the time of conducting the measurement. After completing the whole process participants will be informed about the readings. The measurement of blood pressure will be recorded from the left wrist/arm but in the case of a stroke on that side/limb then it will be measured from the right side.

Blood tests: Blood samples of all the study participants will be drawn at each study site for the biochemical assessment after completion of all the measures using standardised protocols. The blood samples in Pakistan will be transported and investigated at the standardised pathological clinical laboratory of Baqai Institute of Diabetes and Endocrinology, Karachi. In Bangladesh, samples collected for the glycated hemoglobin (HbA1C) will be transported for analysis at the

BIRDEM General Hospital, Dhaka. Glycated haemoglobin (HbA1c) will be assessed at baseline,
6 and 12 months follow-ups. Hemoglobin level (Hb), Complete Blood Count, Random Blood
Glucose (RBG) test, renal function test including serum creatinine and estimated Glomerular
Filtration Rate (eGFR), lipid function test including Total Cholesterol (TC), High-Density
Lipoprotein Cholesterol (HDLC) and Low-Density Lipoprotein Cholesterol (LDLC) will be
assessed at baseline and 6 months. Thyroid-Stimulating Hormone (TSH) test will be performed
only at baseline.

357 <u>Comorbidities and medications:</u> Data on comorbidities and medications will be collected using

358 participant self-report, through a set of questions adapted from the STEPs module for NCDs

[35]. Participants will be asked for a medically diagnosed history of raised blood pressure, heart

disease, hypercholesterolemia, stroke, lung diseases, the treatment offered by their health

361 workers and communicable/ infectious diseases (e.g. Tuberculosis, Malaria, HIV, Hepatitis B, C,

362 Dengue, COVID-19, Chikungunya).

<u>Caseness and severity of depression:</u> The Patient Health Questionnaire-9 (PHQ-9) is a nine item questionnaire and scored from a minimum of 0 to a maximum of 27, with a cut-off of 0–4
 represents no depressive symptoms, 5–9 mild depressive symptoms, 10–14 moderate
 depressive symptoms, 15–19 moderately-severe depressive symptoms, and 20–27 severe
 depressive symptoms [22,30].

<u>Anxiety:</u> The severity of generalised anxiety disorder will be assessed with the use of a
generalised anxiety disorder (GAD-7) [36,37] scale. It is a 7-item scale with scores ranging from
0 to 21, where the scores of 5, 10, and 15 will be taken as cut off points for mild, moderate, and
severe anxiety [36].

<u>Diabetes-related distress:</u> The Problem Area in Diabetes Scale-5 (PAID-5) will be used to
 collect information on diabetes-related emotional distress [38,39]. This scale will assess

common issues and feelings linked with complications of diabetes. The 5-item scale scores range from 0 (not a problem) to 4 (serious problem). The total sum of scores of the PAID scale determines the level of diabetes-related distress and a cut-off of \geq 8 indicates diabetes-related distress [38].

378 Diabetes-related self-efficacy and self-management: Three measures will be used: the 379 Diabetes Empowerment Scale Short Form (DES-SF)[40], Perceived Diabetes Self-Management 380 Scale (PDSMS) [41] and Summary of Self-Care Diabetes Activities scale (SDSCA) [42]. The DES-SF is an 8-item scale to assess general diabetes-related psychosocial self-efficacy. The 8-381 382 item PDSMS measures confidence in self-management with individual scores ranging from 1 (strongly disagree) to 5 (strongly agree) with 4 items being reversed scores. The total score of 383 the PDSMS scale ranges from 8 to 40, with higher scores indicating higher confidence in self-384 management. The 11-itemSDSCA measures diabetes self-management activities related to 385 386 general diet, specific diet, exercise, blood glucose testing, foot care and smoking). Health risk behaviours: Information on physical activity will be collected using the International 387 Physical Activity Questionnaire (IPAQ), a nine-item scale (short version) [43]. The scale 388 measures activities and their intensity over the past seven days i.e. 1) vigorous-intensity activity 389 390 such as aerobics, 2) moderate-intensity activity e.g. leisure cycling, 3) walking and 4) sitting. 391 Current use of smoked or smokeless tobacco in the past 30 days will be assessed through guestions adapted from GATS guestionnaire and the STEPs expanded modules on tobacco 392 393 and smokeless tobacco use [31]. Alcohol use: Questions related to alcohol use, adapted from 394 the STEPs module [31] will also be applied to measure alcohol consumption.

395 <u>Diabetes-related microvascular and macrovascular complications:</u> Current or previous episodes
 396 of macrovascular complications (coronary artery disease, stroke and peripheral arterial disease)

397 along with microvascular complications of diabetes (diabetic nephropathy, neuropathy and 398 retinopathy) will be assessed based on health care staff reporting or by participant's self-report. 399 Health-related quality of life: Eurogol's instrument EQ-5D-5L will be administered to measure 400 health-related quality of life (HRQoL) [44]. EQ-5D is a standardised measure of health status 401 developed by the EuroQol Group. It provides a simple, generic measure of health for clinical 402 and economic appraisal, where health is characterised by five dimensions; mobility, self-care, ability to undertake usual activities, pain/discomfort, and anxiety/ depression [45]. participants' 403 404 subjective evaluation of their health state based on a visual analogue scale (EQ-5D-VAS) is 405 also included in the scale, ranging from 0 (representing the worst imaginable health state) to the maximum attainable value of 100 (indicating the best imaginable health state). 406 407 Measures of potential mediators: Measures of potential mediators consisting of knowledge. 408 goals, behaivoural cuing, intentions and beliefs about consequences adapted from the 409 intervention logic model will be assessed. A mix of seven bespoke and standardised questions 410 will be used: 1)You set goals and keep track of progress; 2) you are motivated to make changes in your daily activities to change your mood; 3) you are willing to make changes in your 411 412 life to improve your mood; 4) you find it easy to make a plan [to achieve your goals]; 5) you have 413 trouble making plans to help you reach your goals 6) your behaviour influences your future 414 emotions; and 7) If you make positive changes now you will feel better in the future. Each statement will be scored on a 5-point Likert type scale, with responses ranging from completely 415 416 agree to completely disagree. In addition, participant's activation will be assessed at 6 and 12 417 months follow-up with the Premium Abbreviated Activation scale (PAAS) [46]. PAAS is a 5-item 418 scale, adapted from the behavioural activation for depression scale (BADS-SF) [47]. PAAS encompasses Behavioral Activation of five indicators on a scale of 0 (not at all) to 5 (yes, 419 completely) with scores ranging from 0 to 25. 420

421

<u>Healthcare resource use and Economic outcomes:</u> Healthcare resource use will be collected
using a modified Client Service Receipt Inventory (CSRI) [48]. Data will be collected on the use
of clinic and outpatient facilities, inpatient stays, tests, imaging and medication, with details of
specialities Information on other economic outcomes including employment status, productivity
loss, catastrophic health spending, household expenditure and household assets will also be
collected.

428 Statistical analysis:

Baseline characteristics will be summarised by the study arm, using means and standard deviations for continuous data and counts and percentages for categorical data. The flow of study participants will be presented in a CONSORT diagram [49] and fidelity with the BA intervention in terms of the number of sessions and duration of the intervention will be detailed. All primary and secondary outcomes will be summarised descriptively at all available time points, including the extent of missing data.

The primary analysis will be on intention to treat (ITT) basis using a linear mixed effects model. 435 comparing PHQ-9 scores between randomised treatment groups at 6 months from a treatment 436 437 group by time interaction term, adjusting for country and PHQ-9 at baseline as fixed effects and including a random effect for therapists, nested within the treatment group. The model will 438 incorporate outcomes from all available time points. The treatment group difference at 6 months 439 440 will be presented as a mean estimate with a 95% confidence interval and associated p-value; the difference at 12 months will be reported as a secondary endpoint. Assumptions of the analysis 441 442 model will be evaluated (normality and data missing at random), and transformation and multiple imputation considered if appropriate. A Complier Average Causal Effects (CACE) analysis will be 443 conducted as a sensitivity analysis, adjusting for compliance with the BA intervention. Estimates 444

of group differences by country will be explored by including a country by treatment group by time
interaction term in the above model as a secondary analysis of the primary outcome.

447 Secondary outcomes will be analysed similarly to the primary analysis model, using linear or 448 logistic mixed models for continuous and binary outcomes respectively. Adverse events will be 449 summarised by treatment arm in terms of the total number of events, adverse events by type and

- the average number of events per participant. There will be no statistical comparison of these.
- 451 Full analysis details will be given in a separate pre-specified statistical analysis plan (SAP).

452 **Process evaluation:**

- 453 A mixed methods process evaluation will aid in understanding the causal mechanisms
- underpinning the intervention, along with understanding how such interventions might be
- 455 implemented and scaled up in practice in primary or secondary healthcare services.
- 456 In line with recent guidance, we will focus on understanding:
- 457 1. Implementation and fidelity of the intervention
- 458 2. Mechanisms of impact of the intervention
- 459 3. How context affects delivery and outcomes

We will use data collected from other parts of the programme as well as specifically for the processevaluation.

462 <u>*Qualitative data collection using a range of methods:*</u> We will collect qualitative data from 463 participants, carers and healthcare staff to explore the responses to the intervention, contextual 464 factors and the mechanisms of action. We will use a range of methods in order to explore these 465 factors in depth, to facilitate discussion and triangulate findings. These may include interviews, 466 focus group discussions and participatory methods such as photovoice. In each country, we will 467 collect data from up to 20 participants, 10 carers, 5 facilitators/supervisors and 3 healthcare

managerial staff (exact numbers will be decided closer to the time and will also depend on
reaching data saturation). We will also collect data from participants and carers in the control arm.
Data will be analysed thematically, comparing data from the controls and any overlap in changes
and contextual factors.

472 <u>*Reports and observations:*</u> The CRFs and session audio recordings will capture important 473 information about the dose and fidelity of the intervention, and behaviour change techniques 474 (BCTs) that were implemented.

475 <u>*Trial data:*</u> Collected at baseline, after completion of BA sessions and at 6- and 12-months post476 randomisation looking at potential mediators derived from the intervention logic model will be
477 analysed, to see which are important and changes that may occur during the intervention.

Findings from the process evaluation will be mapped to an implementation framework to explain how the intervention was delivered, the mechanisms of action and contextual factors. Additionally, it will provide opportunities to generate hypotheses that might explain differential responses among groups of participants. This will inform secondary and pre-planned subgroup analysis of the main trial data to further investigate differential treatment responses.

483 **Economic analyses:**

484 Information on the costs and health effects of alternative interventions are needed to inform the

allocation of limited healthcare resources to meet population health needs. The economic

analysis will provide evidence to consider the value for money of the DiaDeM intervention.

487 Further, it will examine the economic consequences of diabetes and depression more generally.

488 <u>Cost-effectiveness analysis:</u> Cost-effectiveness analysis will examine the value for money of the

489 DiaDeM intervention for individuals with diabetes and depression multimorbidity over the trial

490 period and over the individuals' lifetime. The within-trial analysis will examine the value for

491 money of the DiaDeM intervention compared to optimised usual care over the 12-month trial 492 period. This will be assessed from a healthcare perspective in the base case. Alternative perspectives reflecting broader economic outcomes will also be considered as scenario 493 analyses [50]. Outcomes will be measured in both quality-adjusted life-years (QALYs) and 494 495 disability-adjusted life-years (DALYs), generic measures of health which capture both morbidity 496 and mortality[51]. Resource use will be captured, and costs estimated by applying unit costs to resource use. Cost-effectiveness will be presented using incremental cost-effectiveness ratios 497 and incremental net health benefits and net monetary benefits based on appropriate cost-498 499 effectiveness thresholds [52,53]. Analyses will control for any baseline differences in covariates between patient groups and for 500 501 issues with non-normality of cost and outcome data using appropriate statistical techniques [54]. 502 Missing data will be imputed using imputation with chained equations [55]. Extrapolation of results over a lifetime: Treatment effects observed in the trial on depression and 503 504 other risk factors (e.g., HbA1c) will be incorporated into the previously developed DiaDeM depression and diabetes multimorbidity model to estimate the lifetime cost-effectiveness of 505 506 DiaDeM versus optimised usual care. Evidence on resource use and costs from the trial will 507 also be incorporated into the model. 508 Cost-effectiveness will be presented using incremental cost-effectiveness ratios and incremental 509 net health benefits and net monetary benefits based on appropriate cost-effectiveness thresholds [52,53]. Scenario analyses will also be conducted. 510 511 Evaluating economic impacts of depression and diabetes: Using evidence on depression and 512 diabetes status and economic outcomes (including employment status, productivity loss, 513 catastrophic health spending, household expenditure and household assets) collected in the

trial, the causal impact of disease on economic outcomes will be assessed. A two-stage

515 modelling approach will be employed. First, we will evaluate the distributional impact of DiaDeM 516 using difference-in-differences (DID) analysis to compare outcomes for the DiaDeM treatment 517 arm with the control arm. To account for heterogeneity in the impact of DiaDeM, we will interact the DID estimator with the wealth level of the household, measured by the asset index. This first 518 519 stage will allow us to obtain the predicted measure of depression-diabetes multimorbidity. In the 520 second part, to evaluate the causal impact on economic outcomes, we will regress the predicted 521 measure of depression-diabetes multimorbidity from the first stage, on the economic outcome 522 variables. For each outcome, we will run appropriate regressions. We will take account of socio-523 demographic and other control variables including gender and will run sensitivity checks to ensure the robustness of our models. This approach will help us with the identification problem 524 arising from the fact that several of our economic outcomes can also determine depression (i.e. 525 reverse causality). We will condition on baseline depression status and look at attributed 526 527 changes in the outcome variable to the intervention, i.e., the mental health of participants which 528 is mediated by the impact of the DiaDeM intervention on their depression.

529 Adverse events monitoring:

Although we expect adverse or serious adverse events encountered during the trial will be
minimal, a standard approach to the collection, recording and reporting of adverse and serious
adverse events will be followed in order to ensure the safety of trial participants.

<u>Definition of adverse events:</u> Adverse events (AEs) are defined as an untoward clinical development that may occur in an individual during their participation in a clinical trial. This could be an unfavourable and unintended sign, symptom, or disease that may or may not be related to the treatment provided [56]. In our study population of people with diabetes and depression, a range of potential adverse events could be expected. These include, but may not be limited to: hospitalisation for any given cause, diabetes emergencies like the development of cataracts, partial or complete blindness, development of ulcers, hypersensitivity reactions, hypoglycemia,

540 severe hypoglycemia (hypoglycemic shock), diabetic ketoacidosis (DKA) and hyperosmolar 541 hyperglycemic state (HHS) deterioration of renal function leading to chronic kidney disease 542 (CKD), kidney failure, diabetes complications like angina, myocardial infarction, stroke, transient 543 ischemic attacks, loss of sensation in the feet, diabetic foot, gangrene, limb, foot or toe 544 amputations. Depression-related emergencies (suicidal ideation) captured on the PhQ-9 545 assessment either at baseline or follow-up assessments will also be recorded as an adverse 546 event.

Adverse events will not include medical or surgical procedures other than those identified in the list of potential adverse events above. They will not include pre-existing diseases or hospitalisation in cases where no untoward or unintended response has occurred (elective cosmetic surgery, or social admissions).

551 Identification and reporting of adverse events: Information on adverse events will be collected 552 by RAs as reported by the medical officers at the study sites and/or by the trial participants' self-553 report through the course of their involvement in the trial. Information on the type of expected adverse events, along with information on how to report adverse events in a quarterly newsletter 554 will be mailed to all study participants from the month of their recruitment till the end of follow-up 555 556 activities. Trial participants who contact the study team to report adverse events will be put in touch with the study RA, who will use a pre-designed data collection form to collect the relevant 557 information. 558

The collected adverse events information will be assessed by a designated member of clinical staff at each study site for expectedness, relatedness, and seriousness. The WHO Uppsala Monitoring Centre (WHO-UMC) scale [57] will be used to identify the relatedness of each unexpected event, which will classify events as certain, probable, possible and unlikely. Seriousness will be assessed on the basis of whether the observed event i) results in death ii) is

life-threatening, ii) requires inpatient hospitalisation or prolongation of existing hospitalisation or
iv) results in persistent or significant disability or incapacity.

For expected adverse events, a standard reporting procedure will be followed, whereby the 566 information will be reported at scheduled meetings of the Data Monitoring Committee. Adverse 567 568 events that are classified as serious, unexpected and related to the intervention will require 569 expedited reporting to the Trial Manager and the Principal Investigator who will review the report and inform the York ethics committee within 15 days of the occurrence. Participants reporting 570 571 such events will be followed up until the episode has resolved or an outcome has been reached. Follow-up information, where applicable, will also be sent as soon as it is available. In addition, 572 each study site staff will follow their institution's procedure for local notification and as per the 573 574 guidelines of their local Research Ethics Committees Boards.

575 Trial monitoring and quality assurance:

576 We will ensure that our research activities align with internationally-agreed ethical standards 577 [58,59], and the Medical Research Council's (MRC) guidance on the management of global health trials [60] while at the same time complying with local legislation governing research participation 578 579 and staff employment in Bangladesh and Pakistan. Research staff will be trained (and re-trained 580 in due course, where necessary) on Good Clinical Practices (GCP), and on key trial procedures such as taking informed consent, administering guestionnaires, recording participant responses, 581 582 and maintaining study logs, ethical considerations, and data management. We will follow the 583 University of York and its partners' policies for the safety of staff and research participants. Ethics 584 applications and protocols will detail how this will be monitored and risks mitigated. For UK staff travelling to partner countries, risk assessments will be carried out according to university policy. 585 For LMIC staff working in field settings, risks will be assessed by the site lead and any mitigations 586

587	required will be put in place. We will work within York's Safeguarding Policy, and in line with the
588	statement on standards for safeguarding international development research.[61]
589	A Data Monitoring Committee (DMC) comprising independent members will act as the oversight
590	body for the DiaDeM trial. The DMC will safeguard the interests of trial participants, assess the
591	safety of the interventions during the trial, and monitor the overall conduct of the trial. The DMC
592	will decide the frequency of their meetings before and during the trial to review the progress,
593	and quality of data and monitor AEs. They will monitor the safety of study participants and that
594	they are not exposed to unnecessary risks because of their trial participation.
595	
596	The overall conduct of the trial and its procedures will be monitored regularly by an Independent

Trial Steering Committee (ITSC). The ITSC will provide oversight of the trial procedures to ensure the validity and credibility of the trial, and protocol adherence. The ITSC will also be advised on the conduct of the trial with special reference to the safety of the participants and researchers by the DMC after continuously appraising and evaluating the validity and integrity of the trial data as it is accrued. The trial may be stopped if guided by ITSC and DMC, as per termination guidelines.

603

604 **Community Engagement and Involvement**

605 Community Advisory panels (CAP) will be convened in each country every 6 months throughout 606 the duration of the trial. Each panel will help to ensure the programme remains focused on the 607 prioritised needs of the community and that planned activities are ethically sound, culturally 608 appropriate, feasible and have community support. Panel members will review plans and study 609 materials for recruitment and data collection; they will also advise on and contribute to the 610 dissemination of key findings to participants, healthcare providers, and public. CAP involvement

611 will improve research quality, help engender a sense of ownership of outputs by the community,

help to accelerate uptake and maximise the reach and impact of our programme.

613 **Ethical considerations:**

Formal ethical approvals have been acquired from the Health Sciences Research Governance
Committee (HSRGC), University of York (Ref: HSRGC/2020/409/B), Diabetic Association of
Bangladesh (Ref: BADAS-ERC/EC/20/00300), National Bioethics Committee Pakistan (Ref:
No.4-87/NBC-578/23/1382), Institutional Research and Ethics Forum of Rawalpindi Medical
University (Ref:242/IREF/RMU/2020) and Ethics Committee of the Office of Research Innovation
& Commercialization (ORIC), Khyber Medical University (KMU),(Ref: DIR/KMU/UEC/25),
Pakistan.

The study protocol adheres to the Declaration of Helsinki's principles of human rights and dignity 621 [62]. All research activities will be conducted in accordance with current MRC Good Clinical 622 Practice guidelines [63], the NHS Research Governance Framework [64], and the Mental 623 624 Capacity Act (UK) 2005 [65]. The latter identifies good practices governing the participation of people lacking capacity. All individuals screened for the trial will be provided an information leaflet. 625 626 highlighting the importance of depression screening and possible care pathways for those who 627 have depressive symptoms. For those taking part, we will follow standard procedures for informed consent, maintain participant anonymity and explain the right to withdraw at any time during the 628 629 study. For those who choose to withdraw, we will retain and utilise data gathered up until the day of withdrawal, unless otherwise specified. We will also seek permission to retain contact 630 information for possible contact in the future for other research projects. 631

Adverse events that need expedited reporting will be notified according to the requirements and within the time periods specified in the Adverse events procedures. In the case of abnormal blood reports, or the detection of a comorbid illness based on biochemical assessment or screening

tests/scales, referrals will be made to the relevant medical department. The suicide risk pathway
and standard operational procedure developed for each study site will be followed for those who
are identified as being at risk of self-harm (Supplementary file 9). All participants will be
appropriately reimbursed for their travel for each contact session.

639 Data Management:

640 During the trial, guantitative and gualitative data will be collected through researcher-administered interviews, face-to-face assessments, interviews, observations, photos, and focus groups. For 641 642 screening and blood tests, data will be entered on paper and will then be entered into a secure online, password-protected data entry software. Baseline and follow-up CRFs and information on 643 anthropometric measurements will be entered directly into Qualtrics. This will be done by RAs 644 using handheld tablets at each site. In addition to the above, some DiaDeM intervention sessions 645 646 will be audio recorded, with consent, for the process evaluation and fidelity assessment of 647 intervention delivery. Interviews and focus group discussions will also be audio-recorded. Written notes will also be recorded in hard copies along with screening forms, consent forms and blood 648 reports. Participant logs for completion of fidelity indices, follow-up and withdrawal will be 649 650 recorded using standard electronic templates. All collected data will be stored on a central server at the University of York. 651

Qualitative interviews will be transcribed in the interview language, but linked with the trial ID and will be anonymised before translation for analysis. Digital recordings of the interviews will be stored locally on a temporary basis in a password-protected folder. Once the analysis of the interviews is completed all recorded versions will be erased from digital recorders.

The Trial Statistician/data manager based at the University of York and the country trial data managers will have access to the datasets. They will use verification, validation, and checking procedures to ensure that the data are accurate and comprehensive. All members of the research

team will adhere to the data management policy developed for DiaDeM under the direction of the University of York Trials Unit's Standard Operating Procedures. The research team will ensure the confidentiality and anonymity of participants to those with delegated responsibilities within the trial team. Participants will be assigned a unique ID so that no identifiable information is accessible to non-authorized persons. Moreover, all identifiable information of the participants will be stored at each study site securely; electronic records will be kept under password protection and hard copies will be stored in locked filing cabinets.

666 Secure services available through the University of York (University of York drop-off:

667 <u>https://www.york.ac.uk/it-services/services/dropoff/</u>) will be used to transfer encrypted data

between study sites and the University of York, where necessary. All files transported through

this will be encrypted as zip files using passwords consisting of at least 8 characters with a mix

of letters and numbers in upper and lower case, and punctuation or other symbols. Data

received via drop-off will only be accessed on desktop computers or laptops which are

672 connected to an encrypted server. Moreover, for non-confidential data or non-sensitive data,

researchers will share the data through the DiaDeM team drive on the Google Drive cloud-

based storage platform, or through the University of York <u>drop-off</u> service.

In line with the University of York Research Data Management Policy, all anonymised research data that underpin published results or have long-term value will be retained indefinitely after the completion of trial activities. Upon completion of the DiaDeM activities, all non-anonymised data will be destroyed.

679 **Discussion**

The DiaDeM trial aims to test the potential of a culturally adapted behavioural activation
 intervention (DiaDeM) as a suitable and cost-effective treatment to address depression among

682 individuals with Type 2 Diabetes who are living in South Asian settings. We have identified an 683 evidence-based intervention and further adapted it for cultural appropriateness in South Asian users and settings [28]. Our plans for implementing the trial are based on a robust study design, 684 backed by the use of validated measures for outcome evaluation. Findings of our stand-alone 685 686 feasibility trial of DiaDeM [14] are yet to be published, however, the key message from this work 687 is that the DiaDeM intervention is feasible to deliver in both Bangladesh and Pakistan and is acceptable to both users (to receive) and BA facilitators (to deliver). We have built on the 688 689 experiences and learning from the feasibility trial by further strengthening our training and 690 supervision processes for BA facilitators. We have further refined the intervention materials (eg. the use of more appropriate images/photographs) based on feedback from research staff and 691 participants. No changes were proposed for the intervention content. We have also expanded the 692 693 trial to a third location (BIDE, Karachi), which will ensure a more representative sample in 694 Pakistan.

The DiaDeM trial is the first of its kind to be implemented in South Asia. It uses a task-sharing 695 approach, incorporating non-mental health resources available within existing health facilities to 696 697 address the growing issue of physical and mental multimorbidity. This approach has great 698 relevance for South Asia given its potential for scalability as a feasible and potentially cost-699 effective solution. We anticipate that our real-world evaluation of the DiaDeM intervention will fill 700 in the existing gaps, paving the way for DiaDeM's adaptation, implementation, and further evaluation beyond South Asian settings, with a view to improving health-related and economic 701 702 outcomes in low-resource settings and populations.

703 Acknowledgements

All authors were involved in the development of this protocol, and therefore the author sequence is based on an equal contribution approach [66]. We would also like to acknowledge the DiaDeM

- 706 Program Steering Committee and the Data Monitoring Committee for their oversight, and the
- 707 Community Advisory Panels in Bangladesh and Pakistan for their input in the development of the
- 708 trial protocol.
- 709

710 **Funding:**

- 711 This study is being carried out under the National Institute of Health Research, Global Health Research
- 712 project, [Grant reference: Research & Innovation for Global Health Transformation (RIGHT)
- 713 NIHR200806]. The University of York is the trial sponsor. The views expressed in this publication are
- those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social
- 715 Care. The funders had no role in study design, data collection and analysis, decision to publish, or
- 716 preparation of the manuscript.

717 Conflicts of Interest:

- Authors do not have any conflicts of interests to declare.
- 719 List of supplementary files
- 720 S1- SPIRIT checklist
- 721 S2- TIDieR checklist
- S3 Information leaflet on the recognition of depression
- 723 S4- Consent form for stage 2 screening
- 724 S5- Participant information sheet
- 725 S6- Consent form for trial participation
- 726 S7- DiaDeM logic model

- 727 S8- Optimised usual care leaflet
- 728 S9- Suicide risk pathway and referral procedure

729 **References**

 Yang X, Li Z, Sun J. Effects of Cognitive Behavioral Therapy-Based Intervention on Improving Glycaemic, Psychological, and Physiological Outcomes in Adult Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. *Front Psychiatry* 2020;**11**:711.

- Bădescu SV, Tătaru C, Kobylinska L, *et al.* The association between Diabetes mellitus and
 Depression. *J Med Life* 2016;**9**:120–5.
- Cicek M, Buckley J, Pearson-Stuttard J, *et al.* Characterizing Multimorbidity from Type 2
 Diabetes: Insights from Clustering Approaches. *Endocrinol Metab Clin North Am* 2021;**50**:531–58.
- Matt. Psychological aspects of diabetes. European Medical Journal.
 2020.http://www.emjreviews.com/diabetes/article/psychological-aspects-of-diabetes
 (accessed 21 Sep 2022).
- de Groot M, Kushnick M, Doyle T, *et al.* Depression Among Adults With Diabetes:
 Prevalence, Impact, and Treatment Options. *Diabetes Spectr* 2010;23:15–8.
- Mendenhall E, Norris SA, Shidhaye R, *et al.* Depression and type 2 diabetes in low- and
 middle-income countries: a systematic review. *Diabetes Res Clin Pract* 2014;**103**:276–85.
- Flood D, Seiglie JA, Dunn M, *et al.* The state of diabetes treatment coverage in 55 low income and middle-income countries: a cross-sectional study of nationally representative,
 individual-level data in 680 102 adults. *Lancet Healthy Longev* 2021;2:e340–51.
- 749 8 Federation ID. IDF Diabetes Atlas 10th ed. 2021.
- Basit A, Fawwad A, Qureshi H, *et al.* Prevalence of diabetes, pre-diabetes and associated
 risk factors: second National Diabetes Survey of Pakistan (NDSP), 2016–2017. *BMJ Open* 2018;8:e020961.
- Kant R, Yadav P, Barnwal S, *et al.* Prevalence and predictors of depression in type 2
 diabetes mellitus. *J Educ Health Promot* 2021;**10**:352.
- Farhan A, Ayub AR, Zafar J. Depression In Type-2 Diabetic Patients Presenting To A
 Tertiary Care Hospital In Pakistan. J Ayub Med Coll Abbottabad 2017;29:262–5.

 Zavala GA, Jennings HM, Afaq S, *et al.* Effectiveness and implementation of psychological interventions for depression in people with non-communicable diseases in South Asia:
 Systematic review and meta-analysis. *Int J Ment Health* 2023;:1–25.

- Martin F, Oliver T. Behavioral activation for children and adolescents: a systematic review
 of progress and promise. *Eur Child Adolesc Psychiatry* 2019;**28**:427–41.
- Aslam F, Afaq S, Siddiqui F, *et al.* An adapted behavioural activation intervention (DiaDeM)
 for people with diabetes and depression in South Asia: A feasibility study protocol.
 F1000Res 2022;**11**:887.
- Kring AM, Sloan DM. *Emotion Regulation and Psychopathology: A Transdiagnostic Approach to Etiology and Treatment*. Guilford Press 2009.
- Mir G, Meer S, Cottrell D, *et al.* Adapted behavioural activation for the treatment of
 depression in Muslims. *J Affect Disord* 2015;**180**:190–9.
- 17 Ekers DM, Dawson MS, Bailey E. Dissemination of behavioural activation for depression to
 mental health nurses: training evaluation and benchmarked clinical outcomes. *J Psychiatr* 771 *Ment Health Nurs* 2013;**20**:186–92.
- 18 Ekers D, Richards D, McMillan D, *et al.* Behavioural activation delivered by the non specialist: phase II randomised controlled trial. *Br J Psychiatry* 2011;**198**:66–72.
- 19 Uphoff E, Pires M, Barbui C, *et al.* Behavioural activation therapy for depression in adults with non-communicable diseases. *Cochrane Database Syst Rev* 2020;**8**:CD013461.
- Chan A-W, Tetzlaff JM, Altman DG, *et al.* SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* 2013;**158**:200–7.
- Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two item depression screener. *Med Care* 2003;**41**:1284–92.
- Kroenke Kurt, Spitzer Robert L. The PHQ-9: A New Depression Diagnostic and Severity
 Measure. *Psychiatr Ann* 2002;**32**:509–15.
- First MB, Williams JBW, Karg RS, Spitzer RL: Structured Clinical Interview for DSM-5—
 Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA,
 American Psychiatric Association, 2015. https://www.appi.org/products/structured-clinical interview-for-dsm-5-scid-5 (accessed 5 Feb 2023).
- MODS Programme of Research. Managing multiple health conditions in older adults.
 https://sites.google.com/nihr.ac.uk/mods/home (accessed 8 Feb 2023).
- Kok G, Schaalma H, Ruiter RAC, *et al.* Intervention mapping: protocol for applying health
 psychology theory to prevention programmes. *J Health Psychol* 2004;**9**:85–98.
- Bernal G, Jiménez-Chafey MI, Domenech Rodríguez MM. Cultural adaptation of
 treatments: A resource for considering culture in evidence-based practice. *Prof Psychol Res Pr* 2009;40:361–8.
- Escoffery C, Lebow-Skelley E, Udelson H, *et al.* A scoping study of frameworks for
 adapting public health evidence-based interventions. *Transl Behav Med* 2019;**9**:1–10.

Zavala GA, Afaq S, Anas A, *et al.* Adaptation of a behavioural activation intervention for
 depression in people with diabetes in Bangladesh and Pakistan: DiaDeM intervention. *Glob Implement Res Appl* 2023;3:44–55.

- Ekers D, Webster L, Van Straten A, *et al.* Behavioural activation for depression; an update
 of meta-analysis of effectiveness and sub group analysis. *PLoS One* 2014;**9**:e100100.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
 measure. J Gen Intern Med 2001;16:606–13.
- 802 31 Bonita R, Winkelmann R, Douglas KA, *et al.* The WHO Stepwise Approach to Surveillance
 803 (Steps) of Non-Communicable Disease Risk Factors. In: McQueen DV, Puska P, eds.
 804 *Global Behavioral Risk Factor Surveillance*. Boston, MA: : Springer US 2003. 9–22.
- 32 Zaman MM, Rahman MM, Rahman MR, *et al.* Prevalence of risk factors for non communicable diseases in Bangladesh: Results from STEPS survey 2010. *Indian J Public Health* 2016;**60**:17–25.
- Nishtar S, Bile KM, Ahmed A, *et al.* Integrated population-based surveillance of noncommunicable diseases: the Pakistan model. *Am J Prev Med* 2005;**29**:102–6.
- 810 34 Physical status: the use and interpretation of anthropometry. Report of a WHO Expert
 811 Committee. World Health Organ Tech Rep Ser 1995;854:1–452.
- 812 35 WHO steps surveillance manual: the WHO stepwise approach to chronic disease risk factor 813 surveillance. WHO 2005.
- Spitzer RL, Kroenke K, Williams JBW, *et al.* A brief measure for assessing generalized
 anxiety disorder: the GAD-7. *Arch Intern Med* 2006;**166**:1092–7.
- Swinson RP. The GAD-7 scale was accurate for diagnosing generalised anxiety disorder.
 Evid. Based. Med. 2006;**11**:184.
- McGuire BE, Morrison TG, Hermanns N, *et al.* Short-form measures of diabetes-related
 emotional distress: the Problem Areas in Diabetes Scale (PAID)-5 and PAID-1. *Diabetologia* 2010;**53**:66–9.
- Welch GW, Jacobson AM, Polonsky WH. The Problem Areas in Diabetes Scale. An
 evaluation of its clinical utility. *Diabetes Care* 1997;**20**:760–6.
- 40 Anderson RM, Fitzgerald JT, Gruppen LD, *et al.* The Diabetes Empowerment Scale-Short
 Form (DES-SF). *Diabetes Care* 2003;**26**:1641–2.
- Wallston KA, Rothman RL, Cherrington A. Psychometric properties of the Perceived
 Diabetes Self-Management Scale (PDSMS). *J Behav Med* 2007;**30**:395–401.
- 42 Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities 828 measure: results from 7 studies and a revised scale. *Diabetes Care* 2000;**23**:943–50.
- 43 Lee PH, Macfarlane DJ, Lam TH, *et al.* Validity of the International Physical Activity
 Questionnaire Short Form (IPAQ-SF): a systematic review. *Int J Behav Nutr Phys Act*2011;8:115.
- Feng Y-S, Kohlmann T, Janssen MF, *et al.* Psychometric properties of the EQ-5D-5L: a
 systematic review of the literature. *Qual Life Res* 2021;**30**:647–73.
- 45 Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status Using

- EQ-5D: A European Perspective: Evidence from the EuroQol BIOMED Research Programme. Springer Science & Business Media 2013.
- 46 Weobong B, Weiss HA, McDaid D, *et al.* Sustained effectiveness and cost-effectiveness of
 the Healthy Activity Programme, a brief psychological treatment for depression delivered by
 lay counsellors in primary care: 12-month follow-up of a randomised controlled trial. *PLoS Med* 2017;**14**:e1002385.
- 47 Manos RC, Kanter JW, Luo W. The behavioral activation for depression scale-short form:
 42 development and validation. *Behav Ther* 2011;**42**:726–39.
- 48 Beecham J, Knapp M. COSTING PSYCHIATRIC INTERVENTIONS.
 48 1999.https://www.pssru.ac.uk/pub/dp1536.pdf (accessed 12 Dec 2022).
- 49 Osborne N, Avey MT, Anestidou L, *et al.* Improving animal research reporting standards:
 HARRP, the first step of a unified approach by ICLAS to improve animal research reporting
 standards worldwide. *EMBO Rep* 2018;**19**. doi:10.15252/embr.201846069
- Walker S, Griffin S, Asaria M, *et al.* Striving for a Societal Perspective: A Framework for
 Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision
 Makers. *Appl Health Econ Health Policy* 2019;**17**:577–90.
- 51 Drummond MF, Sculpher MJ, Claxton K, *et al. Methods for the Economic Evaluation of* 52 *Health Care Programmes.* Oxford University Press 2015.
- Woods B, Revill P, Sculpher M, *et al.* Country-Level Cost-Effectiveness Thresholds: Initial
 Estimates and the Need for Further Research. *Value Health* 2016;**19**:929–35.
- S3 Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and
 middle-income countries: a novel approach and evidence from cross-country data. *BMJ Glob Health* 2018;**3**:e000964.
- Barber J, Thompson S. Multiple regression of cost data: use of generalised linear models. J
 Health Serv Res Policy 2004;**9**:197–204.
- White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and
 guidance for practice. *Stat Med* 2011;**30**:377–99.
- S6 Guideline IH. Integrated addendum to ICH E6 (R1): guideline for good clinical practice E6 (R2). *Current Step* 2015;2:1–60.
- S7 Center UM, Health Organization W. The use of the WHO-UMC system for standardised
 case causality assessment. *Im Internet (Stand: 79 2020): https://www*
- 866 58 World Medical Association Declaration of Helsinki. *JAMA* 2013;**310**:2191.
- International Ethical Guidelines for Health-related Research Involving Humans. Fourth.
 Geneva: Council for International Organizations of Medical Sciences (CIOMS) 2016.
- 60 MRC Guidelines for Global Health Trials Involving Clinical or Public Health Interventions.
 870 Version 2.0 (2019). Medical Research Council 2017.
- 871 https://mrc.ukri.org/documents/pdf/guidelines-for-management-of-global-health-trials/

- 61 International Development Research Funders Statement on Safeguarding.
- 2019.https://www.ukri.org/files/international/ukcdr-safeguarding-statement-pdf/ (accessed
 2019).
- Williams JR. The Declaration of Helsinki and public health. *Bull World Health Organ* 2008;**86**:650–2.
- 877 63 Vere D. MRC Guidelines for Good Clinical Practice in Clinical Trials. *J Med Ethics* 878 1999;**25**:280.
- Taylor M. Research governance framework for health and social care. *Health Soc Care Community* 2002;**10**:6–9.
- 65 Johnston C, Liddle J. The Mental Capacity Act 2005: a new framework for healthcare
 decision making. *J Med Ethics* 2007;**33**:94–7.
- 66 Tscharntke T, Hochberg ME, Rand TA, *et al.* Author sequence and credit for contributions in multiauthored publications. *PLoS Biol* 2007;**5**:e18.

	STUDY PERIOD									
	Enrolme nt	Allocatio	Post-allocation (weeks)					Follow-ups		
TIMEPOINTS	-t1	0	w1	w2	w3	w4	w5	w6	6 months	12 months
Recruitment and follow-up:										
Stage 1 and 2 screening	x									
Provision of information and Informed consent	x									
Allocation		х								
Baseline Data collection		х								
Follow-up data collection									х	х
Intervention delivery:										
Behavioural activation (DiaDeM)			ļ					ļ		
Optimised usual care		х								
Details of planned assessments:										
Socio-demographic information		x								
Anthropometric and physical measurements		х							х	х
Blood tests: hemoglobin, complete blood count, random blood sugar		х							х	х

Figure 1. SPIRIT schedule of trial recruitment and follow-up, intervention delivery and assessments

Blood tests: renal function and lipid function	x			х	
Blood tests: thyroid function	x				
Blood tests: Glycosylated Hemoglobin (HbA1C)	x			х	х
Comorbidities and medications	x			х	х
Caseness and severity of depression	x			х	х
Anxiety	X			х	х
Diabetes related: diabetes distress, self-efficacy, self- management, micro and macrovascular complications	X			х	х
Health risk behaviors: physical activity, tobacco, and alcohol use	x			х	х
Health related quality of life	x			х	х
Mediator measures*	X			х	х
Health care resource use and Economic outcomes	×			х	х

* Premium abbreviated activation scale (PAAS) will only be administered at 6 and 12 months



Figure 2. Trial flow diagram

Figure 2- Flow diagram